News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
In 2012, the global biodefense market was evaluated around USD 7.98 billion and is expected to reach approximately USD 16.16 billion by 2022 while registering itself at a compound annual growth rate (CAGR) of 7.32% over the forecast period owing to technological developments in pathogen detection method in the forensic department. A few of the modern technologies employed in biodefense are nanotechnology, database management systems, advanced detector hardware, and gene chips. The rising vaccines production, quick diagnostic procedures, superior detection and forensic therapies, and prophylactics are amongst the crucial factors anticipated to reinforce the biodefense capabilities around the globe over the projected period. Escalating investment by the local government in developed economies, like the Europe and the United States, for biodefense awareness, is expected to boost the growth during the forecast years. According to the report issued by the Centre for Research on Innovation and Science Policy, it was affirmed that the number of grants owed by the National Institutes of Health (NIH) for the progress of bioweapon agents, like anthrax, plague, glanders, brucellosis, and tularemia, had augmented by 15 times over the years, 1996-2001. Due to the augment in the number of co-owned and foreign-owned patents, a number of international associations, subcontracting, and technological collaboration agreements are increasing, which are hence anticipated to drive the market demand in the approaching few years. Furthermore, rising government intervention concerning advancing different initiatives, like the BioShield initiative was undertaken during 2004, and producing payments for private biotech firms to manufacture and develop new vaccines alongside CDC-defined category A bioterrorism threats, like tularemia, botulism, and viral hemorrhagic fevers such as Ebola. The ensuing market opportunity has contributed to collaborations among the private players as well as with several international biotechnology firms in regions, like Japan, France, Denmark, Belgium, Austria, the UK, and the Netherlands, to expand countermeasures beside biological threat agents.
In 2015, Anthrax was the leading application section and reported for a market share of around 31.3%.The rising interest, as well as attempts of private players in escalating the product range providing to anthrax prevention, is expected to drive the industry growth in the approaching years. Rising government investments in the United States to produce and stockpile adequate vaccines against anthrax during various programs, like Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation, and Joint Program Executive Office for Biological and Chemical Defense, is initiating commercial opportunities for this field. The other products section reported for approximately 15% of the overall market during 2015 and is anticipated to grow at a compound annual growth rate of around 8.3% during forecast period. The viral hemorrhagic section is recognized as the most productive sector. Rapid ascend in R&D funding after the Ebola outbreaks over 2014-2015 and rising awareness concerning the prospective of the virus being utilized as a bio-weapon assigns to the abovementioned conclusion. The radiation section is also anticipated to experience rapid expansion over the forecast years. The global market is propelled by expansion in the research and development initiatives subsequent to the nuclear crisis in Japan.
Regional Outlook and Trend Analysis
In 2015, North American market appeared as the major segment reporting for over half of the global industry. Government initiatives concerning to the funding for genetic defense mechanism is a key factor pushing the expansion of the market. Though, fluctuations in financial support owing to altering government regulations might hamper demand over the forecast years. Asia Pacific region is anticipated to experience a major demand owing to rising investments in the R&D segment. Japan and Australia are a couple of the most developed Asia Pacific regional markets. The widespread vaccine production facilities offer across Japan along with the existence of advanced healthcare infrastructure in the nation is leading to its robust industry position.
Competitive Outlook and Trend Analysis
Global biodefense market is comparatively less competitive owing to dedicated nature of the products, and small commercial products demand. The major industry players are Xoma Corporation, PharmAthene, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Medical Systems, Inc., DynPort Vaccine Company, LLC, Cleveland BioLabs, Inc., Bavarian Nordic, Achaogen, Inc., Nanotherapeutics, Inc., and Alnylam Pharmaceuticals, Inc.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
